

a dextrin polymer, wherein said dextrin polymer is modified by succinylation by at least 20mol% characterised in that the stability of the polymer drug conjugate is enhanced.

2. (Amended) The polymer drug conjugate according to Claim 1, wherein said dextrin is succinoylated to at least 30mol%.
3. (Amended) The polymer drug conjugate according to Claim 2, wherein said dextrin is succinoylated from 30% to 40mol%.
4. (Amended) The polymer drug conjugate according to Claim 3, wherein said dextrin is succinoylated from 32% to 36mol%.
5. (Amended) The polymer drug conjugate according to Claim 4, wherein said dextrin is succinoylated to about 34mol%.
6. (Amended) The polymer drug conjugate according to Claim 1, wherein a percentage of α -1-6 linkages in the dextrin is less than 10%.
7. (Amended) The polymer drug conjugate according to Claim 6, wherein the percentage of α -1-6 linkages in the dextrin is less than 5%.
8. (Amended) The polymer drug conjugate according to Claim 1, wherein a molecular weight of the dextrin is in an average molecular weight range 1000-200000.
9. (Amended) The polymer drug conjugate according to Claim 8, wherein a molecular weight of the dextrin is in an average molecular weight range 2000-55000.
10. (Amended) The polymer drug conjugate according to Claim 1, wherein the dextrin contains more than 15% of polymers of DP greater than 12.

11. (Amended) The polymer drug conjugate according to Claim 10, wherein the dextrin contains more than 50% of polymers of DP greater than 12.

12. (Amended) The polymer drug conjugate according to Claim 1, wherein said anti cancer agent is selected from the group consisting of: cyclophosphamide; melphalan; carmusline; methotrexate, 5-fluorouracil; cytarabine; mercaptopurine; anthracyclines; daunorubicin; doxorubicin; epirubicin, vinca alkaloids; vinblastin, vincristine; dactinomycin; mitomycin C; taxol; L-asparaginase; G-CSF; cisplatin; and carboplatin.

Q2
13. (Amended) A pharmaceutical composition, comprising the polymer drug conjugate according to Claim 1 and a pharmaceutically acceptable diluent, excipient or carrier.

14. Please cancel claim 14.

15. Please cancel claim 15.

16. (Amended) A polymer drug conjugate comprising:
at least one biologically active agent; and
a dextrin polymer, wherein said dextrin polymer is modified by succinylation by at least 20mol% characterized in that the stability of the polymer drug conjugate is enhanced.

17. (Amended) The polymer conjugate according to Claim 16, wherein said agent is an imaging agent.

Q3
18. (Amended) The polymer conjugate according to Claim 17, wherein the imaging agent is tyrosinamide.

19. (Amended) The polymer conjugate according to Claim 16, wherein said agent is a diagnostic agent.

20. (Amended) The polymer conjugate according to Claim 16, wherein said agent is a targeting agent.
21. (Amended) The polymer conjugate according to Claim 20, wherein the targeting agent is biotin.
22. (Amended) A method for treating a disease or disorder in an animal subject, comprising:
administering to the animal a pharmaceutically effective amount of the polymer drug conjugate according to Claim 1, thereby treating the disease or disorder in the subject.
23. (Amended) The method according to Claim 22, wherein said animal is human.
-